Gilead hepatitis C drug shows promise in late-stage trial

Tue Nov 27, 2012 9:36am EST

Related Topics

(Reuters) - Gilead Sciences said a late-stage trial of its experimental hepatitis C treatment showed that the virus was not detected in 78 percent of patients taking the drug, 12 weeks after completing therapy.

The trial, named Positron, was testing the drug, sofosbuvir, in patients who were unable or unwilling to take interferon -- a standard hepatitis C drug known for its unpleasant side effects.

No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.

The safety profile of the drug was similar to that observed in prior studies, and there were few treatment discontinuations due to adverse events, Gilead said.

The company said it would submit the full data from the study for presentation at a scientific conference and will share data from additional late-stage studies in early 2013.

Gilead expects to submit its first regulatory filings for sofosbuvir by mid-2013, Chief Scientific Officer Norbert Bischofberger said.

(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
pderoo1 wrote:
Good news! My husband just finished the standard tx plus Incivik this past spring. So far he is undetectable and his doc is calling it a “cure”! Yay!!

Nov 27, 2012 10:48am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.